Browsing by Author "Oguzcan Erbatu"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A Giant Paratesticular Liposarcoma
    (2022) Oguzcan Erbatu; NALAN NESE; TALHA MÜEZZINOGLU
    Liposarcoma is a tumour originating from the mesoderm, which captures nearly twenty percent of all sarcomas. It first described by Lesauvage in 1845. Seventy percent of cases are extremity and retroperitoneum masses. Paratesticular liposarcoma is a rare entity. For treatment, a tumour-free margin radical orchiectomy with wide local excision and high ligation of the spermatic cord should be performed. If needed radiotherapy should be applied. An eighty-six-year-old male patient with paratesticular liposarcoma is reported in this article.
  • No Thumbnail Available
    Item
    Obstructive Uropathy in Advanced Prostate Cancer
    (2023) Oguzcan Erbatu; TALHA MÜEZZINOGLU
    Objective: The incidence of advanced prostate cancer increases in proportion to new treatment options and prolonged life expectancy. Especially in advanced disease, prostate cancer is a progressive disease that can cause obstructive uropathy. This study investigated the relationship between the characteristics of advanced prostate cancer and obstructive uropathy. Materials and Methods: This study retrospectively evaluated the data of prostate adenocarcinoma patients admitted to the Urology Clinic of Manisa Celal Bayar University Hospital between 2017 and 2021. Of them, 48 were advanced prostate cancer patients, and they were all included. All patients in the study received hormonal therapy along with chemotherapy for prostate cancer treatment. The relationship between hydronephrosis and patient age, creatinine and prostatespecific antigen (PSA) values, urinary tract infections, prostate volume, pathological features of cancer, and castration resistance was evaluated. Results: Parameters that we found to be associated with obstructive uropathy (OU) are as follows: high creatinine level at the time of diagnosis of cancer (p<0.001), increase in creatinine at follow-up (p=0.001), urinary infection at the time of diagnosis of cancer (p=0.002) and at follow-up (p=0.003), development of castration resistance during treatment (p=0.038) and high PSA values at the time of diagnosis of prostate cancer (p=0.011). Conclusion: Renal functions should be observed very carefully in advanced prostate cancer patients who develop or are at risk of developing OU. High PSA values and/or castration resistance should be approached carefully in terms of the patients prognosis. It should not be forgotten that their significant relationship with OU has been demonstrated.
  • No Thumbnail Available
    Item
    Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report
    (2023) Levent Türkeri; Oguzcan Erbatu; Bülent Akdoğan; TALHA MÜEZZINOGLU; Tevfik Sinan Sozen; Sümer Baltacı; Evren SÜER; Guven Aslan; Volkan Izol; Oktay Üçer; Suleyman Ataus; Ilker Tinay
    Objective: This report examined the approaches to low-risk patients using the data from the Urologic Cancer Database - Prostate, Urooncology Association. Materials and Methods: In this study, there were 920 patients with low-risk prostate cancer according to the current guidelines of the European Urology Association. Patient data were obtained from the Urological Cancer Database - Prostate, the Turkish Urooncology Association (UroCaD-P) from records of the years 1995-2021. Ethics committee approval was obtained for this study to publish in the form of a database report. Results: Our study was conducted with 920 patients with low-risk prostate cancer. Therefore, at the time of diagnosis, all patients in the study were ISUP 1, had a prostate specific antigen (PSA) level lower than 10 ng/mL, and clinically T1-T2a. Surgical treatment was used in 750 (81.5%) of the patients. At the time patients were retrieved from the database for the study, 140 patients (15.2%) were in the active surveillance (AS) process. Thirty patients (3.2%) in the study received their local treatment as radiotherapy (RT). The mean age value at cancer detection in the study was 61.9. The mean ages of the patients who were under AS and who underwent radical prostatectomy (RP) were 61.3 and 61.7 years, respectively. In the RT group, the mean age was 66.7 years. The mean PSA value of the whole group was 5.81 ng/mL. While it was 5.94 in AS patients, it was calculated as 5.89 in patients who underwent radical surgery. The mean PSA value of the RT group was 5.40. The pathological upgrade was detected in 225 patients (30%) after surgery. Surgical margin positivity was in 160 of the patients (21.3%) who underwent surgery. In addition, 100 patients (13.3%) had extracapsular disease. The seminal vesicle invasion was detected in 25 patients (3.3%) after surgery. Conclusion: We predict that the incidence of low-risk prostate cancer will increase over time due to the aging of the population, the use of PSA, advances in imaging modalities, and increasing biopsy success rates. Therefore, the importance of the existence of multicentric databases containing this patient group is undeniable. More studies are needed with these databases, including both patient demographics and treatment outcomes. Hopefully, this database report will be an important step in this direction.